Author:
Oosterhoff D,Pinedo H M,van der Meulen I H,de Graaf M,Sone T,Kruyt F A,van Beusechem V W,Haisma H J,Gerritsen W R
Publisher
Springer Science and Business Media LLC
Reference28 articles.
1. Arafat W, Gomez-Navarro J, Xiang J, Siegal GP, Alvarez RD, Curiel DT (2000) Antineoplastic effect of anti-erbB-2 intrabody is not correlated with scFv affinity for its target. Cancer Gene Ther 7: 1250–1256
2. Austin EA, Huber BE (1993) A first step in the development of gene therapy for colorectal carcinoma: cloning, sequencing, and expression of Escherichia coli cytosine deaminase. Mol Pharmacol 43: 380–387
3. Chan S, Gabra H, Hill F, Evan G, Sikora K (1987) A novel tumour marker related to the c-myc oncogene product. Mol Cell Probes 1: 73–82
4. Danks MK, Morton CL, Krull EJ, Cheshire PJ, Richmond LB, Naeve CW, Pawlik CA, Houghton PJ, Potter PM (1999) Comparison of activation of CPT-11 by rabbit and human carboxylesterases for use in enzyme/prodrug therapy. Clin Cancer Res 5: 917–924
5. De Graaf M, Boven E, Oosterhoff D, Van der Meulen-Muileman IH, Huls GA, Gerritsen WR, Pinedo HM (2002) A fully human anti-Ep-CAM scFv beta-glucuronidase fusion protein for selective chemotherapy with a glucuronide prodrug. Br J Cancer 86: 811–819
Cited by
35 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献